HIT Consultant October 29, 2024
What You Should Know:
– Quris-AI, a leading Bio-AI company revolutionizing drug development, has acquired Nortis, a pioneer in microphysiology systems (MPS) technology, formerly known as Numa Biosciences.
– The strategic acquisition will integrate Nortis’s advanced Kidney-on-Chip technology into Quris-AI’s Bio-AI platform, enhancing its ability to predict drug safety and efficacy in humans.
Combining Cutting-Edge Technologies
Nortis’s Kidney-on-Chip models have been validated by the National Center for Advancing Translational Sciences (NCATS) and represent a significant advancement in in-vitro drug testing and personalized medicine. By combining this technology with Quris-AI’s machine learning models and patented patient-on-chip system, the company aims to improve the accuracy and efficiency of drug development.
Quris-AI’s Bio-AI Platform: Revolutionizing Drug Development
Quris-AI’s Bio-AI Clinical Prediction...
Today's Sponsors
Today's Sponsor